Current status of myelin replacement therapies in multiple sclerosis

Progress in Brain Research

Volumn 201, Issue , 2012, Pages 219-231

  Huang, Jeffrey K ^a,b   Franklin, Robin J M ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Cell transplantation; CNS myelin; Endogenous adult stem cells; Multiple sclerosis; Oligodendrocyte; Regeneration; Remyelination; Stem cell

Indexed keywords

ALITRETINOIN; BEXAROTENE; IMMUNOMODULATING AGENT; LINGO1 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; MYELIN; PROTEIN; PROTEIN LINGO1; RETINOID X RECEPTOR ALPHA; RETINOID X RECEPTOR BETA; RETINOID X RECEPTOR GAMMA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CENTRAL NERVOUS SYSTEM; DISABILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SCLEROSIS; NERVE CELL DIFFERENTIATION; NERVE FIBER DEGENERATION; NERVE FIBER REGENERATION; NERVOUS SYSTEM INFLAMMATION; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; OLFACTORY ENSHEATHING CELL; OLIGODENDROGLIA; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REMYELINIZATION; SCHWANN CELL;

EID: 84870202838     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-59544-7.00011-1     Document Type: Chapter

References (67)

1. Altucci L., Leibowitz M.D., Ogilvie K.M., de Lera A.R., Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 2007, 6:793-810.
2. Archer D.R., Cuddon P.A., Lipsitz D., Duncan I.D. Myelination of the canine central nervous system by glial cell transplnatation: a model for repair of human myelin disease. Nat. Med. 1997, 3:54-59.
3. Back S.A., Tuohy T.M.F., Chen H., Wallingford N., Craig A., Struve J., Luo N.L., Banine F., Liu Y., Chang A., et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat. Med. 2005, 11:966-972.
4. Ballanger F., Nguyen J.M., Khammari A., Dréno B. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma. Dermatology 2010, 220:370-375.
5. Chang A., Tourtellotte W.W., Rudick R., Trapp B.D. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 2002, 346:165-173.
6. Charles P., Reynolds R., Seilhean D., Rougon G., Aigrot M.S., Niezgoda A., Zalc B., Lubetzki C. Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis?. Brain 2002, 125:1972-1979.
7. Coman I., Barbin G., Charles P., Zalc B., Lubetzki C. Axonal signals in central nervous system myelination, demyelination and remyelination. J. Neurol. Sci. 2005, 233:67-71.
8. Compston A. The basis for treatment in multiple sclerosis. Acta Neurol. Scand. Suppl. 2006, 183:41-47.
9. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
10. Confavreux C., Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006, 129:595-605.
11. Connick P., Kolappan M., Crawley C., Webber D.J., Patani R., Michell A.W., Du M.-Q., Luan S.-L., Altmann D.R., Thompson A.J., et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012, 11:150-156.
12. Cossetti C., AlfaroCervello C., Donegà M., Tyzack G., Pluchino S. New perspectives of tissue remodelling with neural stem and progenitor cell-based therapies. Cell Tissue Res. 2012, 349:321-329.
13. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.Y.D., Karlo J.C., Zinn A.E., Casali B.T., Restivo J.L., Goebel W.D., James M.J., et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
14. Czepiel M., Balasubramaniyan V., Schaafsma W., Stancic M., Mikkers H., Huisman C., Boddeke E., Copray S. Differentiation of induced pluripotent stem cells into functional oligodendrocytes. Glia 2011, 59:882-892.
15. Diab A., Hussain R.Z., Lovett-Racke A.E., Chavis J.A., Drew P.D., Racke M.K. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 148:116-126.
16. Duncan I.D., Goldman S., Macklin W.B., Rao M., Weiner L.P., Reingold S.C. Stem cell therapy in multiple sclerosis: promise and controversy. Mult. Scler. 2008, 14:541-546.
17. Fancy S.P.J., Baranzini S.E., Zhao C., Yuk D.-I., Irvine K.-A., Kaing S., Sanai N., Franklin R.J.M., Rowitch D.H. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev. 2009, 23:1571-1585.
18. Fancy S.P.J., et al. Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat. Neurosci. 2011, 14:1009-1016.
19. Foote A.K., Blakemore W.F. Inflammation stimulates remyelination in areas of chronic demyelination. Brain 2005, 128:528-539.
20. Franklin R.J.M. Remyelination of the demyelinated CNS: the case for and against transplantation of central, peripheral and olfactory glia. Brain Res. Bull. 2002, 57:827-832.
21. Franklin R.J.M. Why does remyelination fail in multiple sclerosis?. Nat. Rev. Neurosci. 2002, 3:705-714.
22. Franklin R.J.M., Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci. 2008, 9:839-855.
23. Franklin R.J.M., Ffrench-Constant C. Stem cell treatments and multiple sclerosis. BMJ 2010, 340:c1387.
24. Freedman M.S., Bar-Or A., Atkins H.L., Karussis D., Frassoni F., Lazarus H., Scolding N., Slavin S., Le Blanc K., Uccelli A. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Mult. Scler. 2010, 16:503-510.
25. Gallo V., Mangin J.-M., Kukley M., Dietrich D. Synapses on NG2-expressing progenitors in the brain: multiple functions?. J. Physiol. (Lond.) 2008, 586:3767-3781.
26. Germain P., Chambon P., Eichele G., Evans R.M., Lazar M.A., Leid M., De Lera A.R., Lotan R., Mangelsdorf D.J., Gronemeyer H. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol. Rev. 2006, 58:760-772.
27. Gilson J., Blakemore W.F. Failure of remyelination in areas of demyelination produced in the spinal cord of old rats. Neuropathol. Appl. Neurobiol. 1993, 19:173-181.
28. Gosselin D., Rivest S. Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis. Neurotherapeutics 2011, 8:643-649.
29. Groves A.K., et al. Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells. Nature 1993, 362:453-455.
30. Hu B.-Y., Du Z.-W., Zhang S.-C. Differentiation of human oligodendrocytes from pluripotent stem cells. Nat. Protoc. 2009, 4:1614-1622.
31. Huang J.K., Fancy S.P.J., Zhao C., Rowitch D.H., Ffrench-Constant C., Franklin R.J.M. Myelin regeneration in multiple sclerosis: targeting endogenous stem cells. Neurotherapeutics 2011, 8:650-658.
32. Huang J.K., Jarjour A.A., Ffrench-Constant C., Franklin R.J.M. Retinoid X receptors as a potential avenue for regenerative medicine in multiple sclerosis. Expert Rev. Neurother. 2011, 11:467-468.
33. Huang J.K., Jarjour A.A., Nait Oumesmar B., Kerninon C., Williams A., Krezel W., Kagechika H., Bauer J., Zhao C., Evercooren A.B.-V., et al. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat. Neurosci. 2011, 14:45-53.
34. John G.R., Shankar S.L., Shafit-Zagardo B., Massimi A., Lee S.C., Raine C.S., Brosnan C.F. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat. Med. 2002, 8:1115-1121.
35. Kotter M.R., Li W.-W., Zhao C., Franklin R.J.M. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J. Neurosci. 2006, 26:328-332.
36. Kotter M.R., Stadelmann C., Hartung H.-P. Enhancing remyelination in disease-can we wrap it up?. Brain 2011, 134:1882-1900.
37. Lefebvre P., Benomar Y., Staels B. Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol. Metab. 2010, 21:676-683.
38. Levine J.M., Reynolds R., Fawcett J.W. The oligodendrocyte precursor cell in health and disease. Trends Neurosci. 2001, 24:39-47.
39. Liu Y., Jiang P., Deng W. OLIG gene targeting in human pluripotent stem cells for motor neuron and oligodendrocyte differentiation. Nat. Protoc. 2011, 6:640-655.
40. Mahad D., Lassmann H., Turnbull D. Review: mitochondria and disease progression in multiple sclerosis. Neuropathol. Appl. Neurobiol. 2008, 34:577-589.
41. Martino G., Franklin R.J.M., Baron Van Evercooren A., Kerr D.A. Stem cell transplantation in multiple sclerosis: current status and future prospects. Nat. Rev. Neurol. 2010, 6:247-255.
42. Martino G., Pluchino S., Bonfanti L., Schwartz M. Brain regeneration in physiology and pathology: the immune signature driving therapeutic plasticity of neural stem cells. Physiol. Rev. 2011, 91:1281-1304.
43. Mi S., Lee X., Shao Z., Thill G., Ji B., Relton J., Levesque M., Allaire N., Perrin S., Sands B., et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat. Neurosci. 2004, 7:221-228.
44. Mi S., Miller R.H., Lee X., Scott M.L., Shulag-Morskaya S., Shao Z., Chang J., Thill G., Levesque M., Zhang M., et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci. 2005, 8:745-751.
45. Mi S., Hu B., Hahm K., Luo Y., Kam Hui E.S., Yuan Q., Wong W.M., Wang L., Su H., Chu T.-H., et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 2007, 13:1228-1233.
46. Mi S., Sandrock A., Miller R.H. LINGO-1 and its role in CNS repair. Int. J. Biochem. Cell Biol. 2008, 40:1971-1978.
47. Mi S., Miller R.H., Tang W., Lee X., Hu B., Wu W., Zhang Y., Shields C.B., Zhang Y., Miklasz S., et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann. Neurol. 2009, 65:304-315.
48. Miller R.H., Mi S. Dissecting demyelination. Nat. Neurosci. 2007, 10:1351-1354.
49. Nishiyama A., Komitova M., Suzuki R., Zhu X. Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. Nat. Rev. Neurosci. 2009, 10:9-22.
50. Paukert M., Bergles D.E. Synaptic communication between neurons and NG2+ cells. Curr. Opin. Neurobiol. 2006, 16:515-521.
51. Pedre X., Mastronardi F., Bruck W., López-Rodas G., Kuhlmann T., Casaccia P. Changed histone acetylation patterns in normal-appearing white matter and early multiple sclerosis lesions. J. Neurosci. 2011, 31:3435-3445.
52. Rist J.M., Franklin R.J.M. Taking ageing into account in remyelination-based therapies for multiple sclerosis. J. Neurol. Sci. 2008, 274:64-67.
53. Ruckh J.M., Zhao J.-W., Shadrach J.L., van Wijngaarden P., Rao T.N., Wagers A.J., Franklin R.J.M. Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell 2012, 10:96-103.
54. Rudick R.A., Mi S., Sandrock A.W. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin. Biol. Ther. 2008, 8:1561-1570.
55. Scolding N., Franklin R., Stevens S., Heldin C.H., Compston A., Newcombe J. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain 1998, 121(Pt 12):2221-2228.
56. Setzu A., Lathia J.D., Zhao C., Wells K., Rao M.S., Ffrench-Constant C., Franklin R.J.M. Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells. Glia 2006, 54:297-303.
57. Shen S., Sandoval J., Swiss V.A., Li J., Dupree J., Franklin R.J.M., Casaccia-Bonnefil P. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat. Neurosci. 2008, 11:1024-1034.
58. Sim F.J., Zhao C., Penderis J., Franklin R.J.M. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J. Neurosci. 2002, 22:2451-2459.
59. Sloane J.A., Batt C., Ma Y., Harris Z.M., Trapp B., Vartanian T. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11555-11560.
60. Syed Y.A., Hand E., Möbius W., Zhao C., Hofer M., Nave K.A., Kotter M.R. Inhibition of CNS remyelination by the presence of semaphorin 3A. J. Neurosci. 2011, 31:3719-3728.
61. Trapp B.D., Nave K.-A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
62. Trapp B.D., Stys P.K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009, 8:280-291.
63. Uccelli A., Benvenuto F., Laroni A., Giunti D. Neuroprotective features of mesenchymal stem cells. Best Pract. Res. Clin. Haematol. 2011, 24:59-64.
64. Uccelli A., Laroni A., Freedman M.S. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol. 2011, 10:649-656.
65. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J. Neurosci. 1998, 18:601-609.
66. Xu J., Drew P.D. 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J. Neuroimmunol. 2006, 171:135-144.
67. Zawadzka M., et al. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell 2010, 6:578-590.